Caitlin C. Zebley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Caitlin C. Zebley has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Ben Youngblood
Department of Immunology, St. Jude Children’s Research Hospital, Memphis, USA
11 shared publications Shanta Alli
Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA
4 shared publications- Dietmar Zehn
Institute for Molecular Medicine and Cell Research, Albert Ludwig University of Freiburg, Freiburg, Germany
3 shared publications - Shanta Alli
Department of Immunology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA
3 shared publications Stephen Gottschalk
Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA
3 shared publications- Stephen Gottschalk
Department of Bone Marrow Transplantation & Cellular Therapy, St. Jude Children’s Research Hospital, Memphis, TN
3 shared publications
Latest Publications
- 15 October 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (11) , 2197-2199
Tuning T cells to give cancer the blues
- 15 October 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (11) , 2197-2199
Tuning T cells to give cancer the blues
- 27 October 2025
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 26 (1) , 46-61
Epigenetic regulation of T cell exhaustion in cancer
Current T cell-based immunotherapy strategies, including immune checkpoint blockade (ICB) and chimeric antigen receptor (CAR) T cells, have revolutionized cancer care. However, many patients with cancer who are treated with these approaches fail to respond or do not achieve durable protection against disease relapse, highlighting the need for further optimization of such strategies. The advent of cancer immunotherapy has ushered in an era of research centred on immune oncology with a specific focus on defining T cell-intrinsic mechanisms that delineate therapeutic responders and non-responders. Among the major barriers limiting immunotherapy efficacy, T cell exhaustion — which is characterized by repression of the effector functions and proliferative potential of T cells — has emerged as a common mechanism among various cancers. Here, we review transcriptional and epigenetic mechanisms that control T cell exhaustion. We discuss how T cell subset-specific gene regulatory programmes limit immunotherapy success and theorize on the development of next-generation strategies for increasing the clinical breadth, efficacy and durability of T cell immunotherapy.
- 27 October 2025
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 26 (1) , 46-61
Epigenetic regulation of T cell exhaustion in cancer
Current T cell-based immunotherapy strategies, including immune checkpoint blockade (ICB) and chimeric antigen receptor (CAR) T cells, have revolutionized cancer care. However, many patients with cancer who are treated with these approaches fail to respond or do not achieve durable protection against disease relapse, highlighting the need for further optimization of such strategies. The advent of cancer immunotherapy has ushered in an era of research centred on immune oncology with a specific focus on defining T cell-intrinsic mechanisms that delineate therapeutic responders and non-responders. Among the major barriers limiting immunotherapy efficacy, T cell exhaustion — which is characterized by repression of the effector functions and proliferative potential of T cells — has emerged as a common mechanism among various cancers. Here, we review transcriptional and epigenetic mechanisms that control T cell exhaustion. We discuss how T cell subset-specific gene regulatory programmes limit immunotherapy success and theorize on the development of next-generation strategies for increasing the clinical breadth, efficacy and durability of T cell immunotherapy.
- 24 January 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (2) , 165-167
ImmunOctoberfest reloaded
- 24 January 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (2) , 165-167
ImmunOctoberfest reloaded
- Top Cited Papers
- 11 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 386 (6718) , eadl4492
Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy
Epigenetic reinforcement of T cell exhaustion is known to be a major barrier limiting T cell responses during immunotherapy. However, the core epigenetic regulators restricting antitumor immunity during prolonged antigen exposure are not clear. We investigated three commonly mutated epigenetic regulators that promote clonal hematopoiesis to determine whether they affect T cell stemness and response to checkpoint blockade immunotherapy. CD8 T cells lacking Dnmt3a, Tet2, or Asxl1 preserved a progenitor-exhausted (Tpex) population for more than 1 year during chronic antigen exposure without undergoing malignant transformation. Asxl1 controlled the self-renewal capacity of T cells and reduced CD8 T cell differentiation through H2AK119 ubiquitination and epigenetic modification of the polycomb group–repressive deubiquitinase pathway. Asxl1-deficient T cells synergized with anti–PD-L1 immunotherapy to improve tumor control in experimental models and conferred a survival advantage to mutated T cells from treated patients.
- 11 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 386 (6718) , eadl4492
Top Cited PapersEpigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy
Epigenetic reinforcement of T cell exhaustion is known to be a major barrier limiting T cell responses during immunotherapy. However, the core epigenetic regulators restricting antitumor immunity during prolonged antigen exposure are not clear. We investigated three commonly mutated epigenetic regulators that promote clonal hematopoiesis to determine whether they affect T cell stemness and response to checkpoint blockade immunotherapy. CD8 T cells lacking Dnmt3a, Tet2, or Asxl1 preserved a progenitor-exhausted (Tpex) population for more than 1 year during chronic antigen exposure without undergoing malignant transformation. Asxl1 controlled the self-renewal capacity of T cells and reduced CD8 T cell differentiation through H2AK119 ubiquitination and epigenetic modification of the polycomb group–repressive deubiquitinase pathway. Asxl1-deficient T cells synergized with anti–PD-L1 immunotherapy to improve tumor control in experimental models and conferred a survival advantage to mutated T cells from treated patients.
- Top Cited Papers
- 18 July 2024
- Published by Springer Nature in Nature Immunology
- Vol. 25 (8) , 1344-1354
T cell dysfunction and therapeutic intervention in cancer
Recent advances in immunotherapy have affirmed the curative potential of T cell-based approaches for treating relapsed and refractory cancers. However, the therapeutic efficacy is limited in part owing to the ability of cancers to evade immunosurveillance and adapt to immunological pressure. In this Review, we provide a brief overview of cancer-mediated immunosuppressive mechanisms with a specific focus on the repression of the surveillance and effector function of T cells. We discuss CD8+ T cell exhaustion and functional heterogeneity and describe strategies for targeting the molecular checkpoints that restrict T cell differentiation and effector function to bolster immunotherapeutic effects. We also delineate the emerging contributions of the tumor microenvironment to T cell metabolism and conclude by highlighting discovery-based approaches for developing future cellular therapies. Continued exploration of T cell biology and engineering hold great promise for advancing therapeutic interventions for cancer.
- 18 July 2024
- Published by Springer Nature in Nature Immunology
- Vol. 25 (8) , 1344-1354
Top Cited PapersT cell dysfunction and therapeutic intervention in cancer
Recent advances in immunotherapy have affirmed the curative potential of T cell-based approaches for treating relapsed and refractory cancers. However, the therapeutic efficacy is limited in part owing to the ability of cancers to evade immunosurveillance and adapt to immunological pressure. In this Review, we provide a brief overview of cancer-mediated immunosuppressive mechanisms with a specific focus on the repression of the surveillance and effector function of T cells. We discuss CD8+ T cell exhaustion and functional heterogeneity and describe strategies for targeting the molecular checkpoints that restrict T cell differentiation and effector function to bolster immunotherapeutic effects. We also delineate the emerging contributions of the tumor microenvironment to T cell metabolism and conclude by highlighting discovery-based approaches for developing future cellular therapies. Continued exploration of T cell biology and engineering hold great promise for advancing therapeutic interventions for cancer.
- Open Access
- 12 June 2024
- Published by Springer Nature in Nature Aging
- Vol. 4 (8) , 1053-1063
Conserved epigenetic hallmarks of T cell aging during immunity and malignancy
Chronological aging correlates with epigenetic modifications at specific loci, calibrated to species lifespan. Such ‘epigenetic clocks’ appear conserved among mammals, but whether they are cell autonomous and restricted by maximal organismal lifespan remains unknown. We used a multilifetime murine model of repeat vaccination and memory T cell transplantation to test whether epigenetic aging tracks with cellular replication and if such clocks continue ‘counting’ beyond species lifespan. Here we found that memory T cell epigenetic clocks tick independently of host age and continue through four lifetimes. Instead of recording chronological time, T cells recorded proliferative experience through modification of cell cycle regulatory genes. Applying this epigenetic profile across a range of human T cell contexts, we found that naive T cells appeared ‘young’ regardless of organism age, while in pediatric patients, T cell acute lymphoblastic leukemia appeared to have epigenetically aged for up to 200 years. Thus, T cell epigenetic clocks measure replicative history and can continue to accumulate well-beyond organismal lifespan.
- 12 June 2024
- Published by Springer Nature in Nature Aging
- Vol. 4 (8) , 1053-1063
Open AccessConserved epigenetic hallmarks of T cell aging during immunity and malignancy
Chronological aging correlates with epigenetic modifications at specific loci, calibrated to species lifespan. Such ‘epigenetic clocks’ appear conserved among mammals, but whether they are cell autonomous and restricted by maximal organismal lifespan remains unknown. We used a multilifetime murine model of repeat vaccination and memory T cell transplantation to test whether epigenetic aging tracks with cellular replication and if such clocks continue ‘counting’ beyond species lifespan. Here we found that memory T cell epigenetic clocks tick independently of host age and continue through four lifetimes. Instead of recording chronological time, T cells recorded proliferative experience through modification of cell cycle regulatory genes. Applying this epigenetic profile across a range of human T cell contexts, we found that naive T cells appeared ‘young’ regardless of organism age, while in pediatric patients, T cell acute lymphoblastic leukemia appeared to have epigenetically aged for up to 200 years. Thus, T cell epigenetic clocks measure replicative history and can continue to accumulate well-beyond organismal lifespan.
- 29 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (87) , eadg3868
Cellular and molecular waypoints along the path of T cell exhaustion
Thirty years of foundational research investigating molecular and cellular mechanisms promoting T cell exhaustion are now enabling rational design of T cell–based therapies for the treatment of chronic infections and cancer. Once described as a static cell fate, it is now well appreciated that the developmental path toward exhaustion is composed of a heterogeneous pool of cells with varying degrees of effector potential that ultimately converge on a terminally differentiated state. Recent description of the developmental stages along the differentiation trajectory of T cell exhaustion has provided insight into past immunotherapeutic success and future opportunities. Here, we discuss the hallmarks of distinct developmental stages occurring along the path to T cell dysfunction and the impact of these discrete CD8 + T cell fates on cancer immunotherapy.
- 29 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (87) , eadg3868
Cellular and molecular waypoints along the path of T cell exhaustion
Thirty years of foundational research investigating molecular and cellular mechanisms promoting T cell exhaustion are now enabling rational design of T cell–based therapies for the treatment of chronic infections and cancer. Once described as a static cell fate, it is now well appreciated that the developmental path toward exhaustion is composed of a heterogeneous pool of cells with varying degrees of effector potential that ultimately converge on a terminally differentiated state. Recent description of the developmental stages along the differentiation trajectory of T cell exhaustion has provided insight into past immunotherapeutic success and future opportunities. Here, we discuss the hallmarks of distinct developmental stages occurring along the path to T cell dysfunction and the impact of these discrete CD8 + T cell fates on cancer immunotherapy.
- 31 March 2023
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 21 (3.5) , YIA23-003
YIA23-003: CD19-CAR T Cells Develop Exhaustion Epigenetic Programs During a Clinical Response
"YIA23-003: CD19-CAR T Cells Develop Exhaustion Epigenetic Programs During a Clinical Response" published on 31 Mar 2023 by National Comprehensive Cancer Network.
- 31 March 2023
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 21 (3.5) , YIA23-003
YIA23-003: CD19-CAR T Cells Develop Exhaustion Epigenetic Programs During a Clinical Response
"YIA23-003: CD19-CAR T Cells Develop Exhaustion Epigenetic Programs During a Clinical Response" published on 31 Mar 2023 by National Comprehensive Cancer Network.
- 21 March 2023
- Published by Elsevier in Trends in Immunology
- Vol. 44 (6) , 397-398
T cell TET2 disruption cuts the breaks on antitumor CAR T cell therapy
- 21 March 2023
- Published by Elsevier in Trends in Immunology
- Vol. 44 (6) , 397-398
T cell TET2 disruption cuts the breaks on antitumor CAR T cell therapy